The deal gives Axiogenesis access to IP that will allow it to commercialize stem cell-derived assays and disease models for use in drug discovery.
NEW YORK (GenomeWeb News) – Cambridge, UK-based Definigen said today that it has raised a total of £2.3 million ($3.8 million) in a Series A round of funding.
By a GenomeWeb staff reporter
CIT will distribute Stemina's devTOX assay in Europe, and the two companies will develop other technologies to assess the safety of compounds for animal and human use.
The firm is placing 7 million shares with a private investment partnership. It has not stated its intended use for the proceeds.
Cellular Dynamics International and Promega are embarking on a research collaboration to validate stem cell-based assays that can be used during drug development.
Researchers from the National Cancer Institute have developed an assay in mouse embryonic stem cells to distinguish between deleterious and neutral human BRCA1 mutations.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.